Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

USP Part D model formulary guidelines

Executive Summary

U.S. Pharmacopeia plans to release a draft version of its Medicare Part D model formulary guidelines 4.0 for the 2009 benefit year on Nov. 6, 2007. Comments on the draft will be accepted until Dec. 31, 2007, and a final version is scheduled to be forwarded to CMS by Feb. 4, 2008. USP's model guidelines expert committee is scheduled to consider the 4.0 version in a closed meeting scheduled for Oct. 1. Comments on the guidelines and requests for revision are accepted by USP throughout the year. The guidelines are used by CMS as a framework for reviewing formulary submissions by Part D plans...

You may also be interested in...



Merck’s ‘COVID Pill’ Shows Promise, But Mortality Benefits Will Be Hard To Prove

Early results from its novel antiviral are encouraging, but demonstrating life-saving qualities in a short window of time will be tricky.

ROI For US With FDA's Emergency Use Approval Of Cue Health's OTC At-Home COVID-19 Test

After federal agencies invested almost $5600m to ensure Cue Health could scale up production, FDA announces the self-administered test will be available OTC. it's the agency's first emergency use authorization for an at-home molecular diagnostic test available nonprescription.

AstraZeneca & Amgen Seek EU Fast-Track For Severe Asthma Drug

Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel